CD40 and neoplasm: Many synthetic TLR3 agonists have been produced and their potential is being tested as adjuvants for vaccines or in combination with ICB, costimulatory agonist (anti-CD40), anti-angiogenic drug (bevacizumab), radiation, tumor-targeted therapy (oregovomab) or lenalidomide.